Home › Funds › Caligan Partners LP › SABS
Caligan Partners LP position in SABS
SAB BIOTHERAPEUTICS INC · Health Care
Caligan Partners LP reported holding 8,736,898 shares of SABS (SAB BIOTHERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$27.7M, representing 1.69% of its reported portfolio and ranking #17 among its reported holdings. Caligan Partners LP has disclosed SABS holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Caligan Partners LP's SABS position evolved
Caligan Partners LP first disclosed a stake in SABS in Q1 2026 at 7,967,207 shares (US$30.5M). The position peaked in Q2 2026 at 7,967,207 shares, worth US$31.1M. Across 3 filings, Caligan Partners LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 8,736,898 shares valued at US$27.7M — an increase of 769,691 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 7.97M | $30.51M | New |
| Q2 2026 | 7.97M | $31.07M | Hold |
| Q3 2026 | 8.74M | $27.70M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SABS and 13F data
SABS (SAB BIOTHERAPEUTICS INC) is a Health Care company. 71 other funds we track also report a position in SABS — the largest reported positions include Vivo Capital, LLC (US$21.9M), PERCEPTIVE ADVISORS LLC (US$21.0M), Commodore Capital LP (US$9.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SABS
- Vivo Capital, LLC 6.92M sh · $21.92M · Q3 2026
- PERCEPTIVE ADVISORS LLC 6.63M sh · $21.01M · Q3 2026
- Commodore Capital LP 2.87M sh · $9.10M · Q3 2026
- Boxer Capital Management, LLC 2.50M sh · $7.92M · Q3 2026
- Spruce Street Capital LP 2.20M sh · $6.97M · Q3 2026
- Sanofi 2.20M sh · $6.97M · Q3 2026
- Sessa Capital IM, L.P. 2.20M sh · $6.97M · Q3 2026
- Propel Bio Management, LLC 1.19M sh · $3.76M · Q3 2026
- Seven Fleet Capital Management LP 752.77K sh · $2.39M · Q3 2026
- DV EQUITIES, LLC 400.00K sh · $1.27M · Q3 2026
More on Caligan Partners LP
FAQ
How long has Caligan Partners LP held SABS?
Caligan Partners LP has disclosed SABS holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Caligan Partners LP's current position in SABS?
As of Q3 2026, Caligan Partners LP holds 8.74M shares of SABS (SAB BIOTHERAPEUTICS INC), valued at $27.70M, representing 1.69% of its reported portfolio and ranking #17.
Has Caligan Partners LP been buying or selling SABS?
In the latest 13F filing (Q3 2026), Caligan Partners LP increased its position in SABS. The position peaked in Q2 2026 at 7.97M shares.
Which other funds hold SABS?
Other major institutional holders of SABS include Vivo Capital, LLC, PERCEPTIVE ADVISORS LLC, Commodore Capital LP, among 71 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.